CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 19-766 S049

Trade Name: Zocor Tablets

Generic Name: simvastatin

Sponsor: Merck & Company, Inc

Approval Date: June 4, 2001
## Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/ Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
CENTRAL FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 19-766 S049

APPROVAL LETTER
NDA 19-766/S-049

Merck & Co., Inc.
Attention: Michael C. Elia, Ph.D., DABT
Director, Regulatory Affairs
Sumneytown Pike, P.O. Box 4, BLA-20
West Point, PA 19486

Dear Dr. Elia:

Please refer to your supplemental new drug application dated February 15, 2001, received February 16, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zocor (simvastatin) tablets.

This supplemental new drug application provides for the addition of a 1000 count HDPE bottle for 5, 40, and 80 mg tablets.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Margaret Simoneau, R.Ph., Regulatory Project Manager, at (301) 827-6411.

Sincerely,

{See appended electronic signature page}

Stephen K. Moore, Ph.D.
Chemistry Team Leader I, DNDC II for the Division of Metabolic and Endocrine Drug Products, (HFD-510)
DNDC II, Office of New Drug Chemistry Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
----------------------
Stephen Moore
6/4/01 01:55:45 PM
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 19-766 S049

CHEMISTRY REVIEW(S)
### CHEMIST'S REVIEW

| 1. ORGANIZATION | CDER/HFD-510  
Division of Metabolism and Endocrine Drug Products |
|------------------|--------------------------------------------------|
| 3. NAME AND ADDRESS OF APPLICANT | Merck & Co., Inc.  
P.O. Box 4  
West Point PA 19486 (Phone): 610-397-2944 |
| 4. SUPPLEMENT | SCS-049  
15-FEB-2001 (Rec. 16-FEB-2001) |
| 5. Name of the Drug | ZOCOR™ |
| 6. Nonproprietary Name | Simvastatin |
| 7. SUPPLEMENT PROVIDES | for the addition of a 1000 count HDPE bottle for 5, 40, and 80 mg tablets. |
| 8. AMENDMENT | |
| 9. PHARMACOLOGICAL CATEGORY | HMG-CoA inhibitor used to treat hyperlipidemia |
| 10. HOW DISPENSED | Oral |
| 11. RELATED | -N. A. - |
| 12. DOSAGE FORM | Tablet |
| 13. POTENCY | 5, 10, 20, 40, 80 mg |
| 14. CHEMICAL NAME AND STRUCTURE | Butanoic acid, 2,2-dimethyl-1,2,3,7,8,8α-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1α,3α,7β,8β(2S*,4S*)]-8αβ]]; C₂₅H₃₈O₅, F.W. = 418.57, CAS 56180-94-0 (For the structure, see Chemistry Review #1, dated 16-MAR-1988 in Vol. 3.1 of NDA 19-766). |
| 15. COMMENTS | See next page. |
| 16. CONCLUSIONS AND RECOMMENDATIONS | Satisfactory CMC information has been provided to support the addition of a 1000 count HDPE bottle for ZOCOR 5, 40, and 80 mg tablets. From the Chemistry point of view, this supplement can be approved. |
| 17. REVIEWER NAME (AND SIGNATURE) | 31-MAY-2001  
Sharon Kelly, PhD  
R/D INITIATED BY |
| DATE | |
| filename: 19766#49 NDASup |

DISTRIBUTION: Original: sNDA 19-766  
cc: HFD-510 Division File  
CSO Reviewer  
AP
2 Page(s) Withheld

\(\_\_\_\) § 552(b)(4) Trade Secret /
Confidential

\(\_\_\_\) § 552(b)(4) Draft Labeling

\(\_\_\_\) § 552(b)(5) Deliberative Process
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-------------------
Sharon Kelly
5/31/01 04:36:58 PM
CHEMIST

paper copy signed May 31; Submission is in EDR

Stephen Moore
5/31/01 05:28:26 PM
CHEMIST
NDA 19-766/S-049

PRIOR APPROVAL SUPPLEMENT

Merck & Co., Inc.
Attention: Michael C. Elia, Ph.D., DABT
Director, Regulatory Affairs
Sumneytown Pike, P.O. Box 4, BLA-20
West Point, PA 19486

Dear Dr. Elia:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Zocor (simvastatin) Tablets

NDA Number: 19-766

Supplement Number: S-049

Date of Supplement: February 15, 2001

Date of Receipt: February 16, 2001

This supplement proposes the addition of a 1000 count package for Zocor 5 mg, 40 mg, and 80 mg tablets.

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on April 17, 2001, in accordance with 21 CFR 314.101(a). If the application is filed, the primary user fee goal date will be June 16, 2001, and the secondary user fee goal date will be August 16, 2001.

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:
U.S. Postal Service/Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Metabolic and Endocrine Drug Products, HFD-510
Attention: Division Document Room, 14B-19
5600 Fishers Lane
Rockville, Maryland 20857

If you have any questions, call me at (301) 827-6411.

Sincerely,

(See appended electronic signature page)

Margaret Simoneau, R.Ph.
Regulatory Project Manager
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research
/s/
------------------
Margaret Simoneau
2/23/01 02:16:44 PM